Some evidence suggests that these drugs may prevent fibrosis and cancer in existing NAFLD; however, more studies are needed, and no studies have examined if ACE inhibitors can prevent the development of NAFLD (Jonsson et al., 2001; Moreno et al., 2010; Li et al., 2018). Here, ACE is linked to metabolic dysfunction-associated steatotic liver disease.